FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806564260> ?p ?o ?g. }

• W2806564260 endingPage "68" @default.
• W2806564260 startingPage "60" @default.
• W2806564260 abstract "Optimal efavirenz (EFV) dose that minimizes adverse effects while maintaining efficacy has yet to be elucidated. With a therapeutic drug monitoring (TDM)-guided strategy, we assessed the effectiveness of half-a-tablet EFV plus 2 nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) in HIV-infected Taiwanese who had achieved viral suppression with full-dose (600 mg) EFV.HIV-infected adults receiving EFV-containing regimens who had plasma mid-dose EFV concentration (C12) ≥2.0 mg/L and had plasma HIV RNA load (PVL) <200 copies/mL were enrolled in this single-arm, open-label study by reducing EFV to half-a-tablet daily. The primary endpoint was PVL <50 copies/ml in an intention-to-treat (ITT) population at week 48. The secondary endpoints were the plasma EFV C12, the proportion of patients with plasma EFV C12 <1.0 mg/L, PVL <50 copies/ml at week 96 and week 144.Between April 2013 and September 2016, 203 patients (93.6% male; median age, 39.0 years) were enrolled. The median EFV C12 before switch was 2.80 mg/L (interquartile range (IQR), 2.41-3.73), which decreased to 1.59 mg/L (IQR, 1.23-2.03) after switch with a reduction of 47.4% (IQR, 38.3-55.5%). In ITT analysis, 93.6%, 92.3% and 87.3% of the patients achieved PVL <50 copies/ml at weeks 48, 96 and 144, respectively. More than 70% of the patients reported alleviation of EFV-associated adverse effects following the switch.Under the guidance of TDM, switch to half-a-tablet EFV plus 2 NRTIs is effective in maintaining viral suppression in HIV-infected Taiwanese with EFV C12 ≥ 2.0 mg/L." @default.
• W2806564260 created "2018-06-13" @default.
• W2806564260 creator A5005558061 @default.
• W2806564260 creator A5020276376 @default.
• W2806564260 creator A5024388162 @default.
• W2806564260 creator A5025368461 @default.
• W2806564260 creator A5051731266 @default.
• W2806564260 creator A5055743677 @default.
• W2806564260 creator A5056134477 @default.
• W2806564260 creator A5064613277 @default.
• W2806564260 creator A5078602610 @default.
• W2806564260 date "2020-02-01" @default.
• W2806564260 modified "2023-10-18" @default.
• W2806564260 title "Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study" @default.
• W2806564260 cites W1607895158 @default.
• W2806564260 cites W1910280141 @default.
• W2806564260 cites W1980345589 @default.
• W2806564260 cites W1981458531 @default.
• W2806564260 cites W1984146020 @default.
• W2806564260 cites W2003396355 @default.
• W2806564260 cites W2003715052 @default.
• W2806564260 cites W2041190841 @default.
• W2806564260 cites W2056557576 @default.
• W2806564260 cites W2059157689 @default.
• W2806564260 cites W2099746597 @default.
• W2806564260 cites W2106737113 @default.
• W2806564260 cites W2110868212 @default.
• W2806564260 cites W2116356899 @default.
• W2806564260 cites W2136559058 @default.
• W2806564260 cites W2137617937 @default.
• W2806564260 cites W2184719281 @default.
• W2806564260 cites W2196612948 @default.
• W2806564260 cites W2249519921 @default.
• W2806564260 cites W2313132761 @default.
• W2806564260 cites W2323671388 @default.
• W2806564260 cites W2329942425 @default.
• W2806564260 cites W2345871675 @default.
• W2806564260 cites W2510140996 @default.
• W2806564260 cites W2590792679 @default.
• W2806564260 cites W2729724518 @default.
• W2806564260 cites W2768680992 @default.
• W2806564260 cites W2091726397 @default.
• W2806564260 doi "https://doi.org/10.1016/j.jmii.2018.05.001" @default.
• W2806564260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29884449" @default.
• W2806564260 hasPublicationYear "2020" @default.
• W2806564260 type Work @default.
• W2806564260 sameAs 2806564260 @default.
• W2806564260 citedByCount "4" @default.
• W2806564260 countsByYear W28065642602020 @default.
• W2806564260 countsByYear W28065642602021 @default.
• W2806564260 countsByYear W28065642602023 @default.
• W2806564260 crossrefType "journal-article" @default.
• W2806564260 hasAuthorship W2806564260A5005558061 @default.
• W2806564260 hasAuthorship W2806564260A5020276376 @default.
• W2806564260 hasAuthorship W2806564260A5024388162 @default.
• W2806564260 hasAuthorship W2806564260A5025368461 @default.
• W2806564260 hasAuthorship W2806564260A5051731266 @default.
• W2806564260 hasAuthorship W2806564260A5055743677 @default.
• W2806564260 hasAuthorship W2806564260A5056134477 @default.
• W2806564260 hasAuthorship W2806564260A5064613277 @default.
• W2806564260 hasAuthorship W2806564260A5078602610 @default.
• W2806564260 hasBestOaLocation W28065642601 @default.
• W2806564260 hasConcept C112705442 @default.
• W2806564260 hasConcept C119060515 @default.
• W2806564260 hasConcept C126322002 @default.
• W2806564260 hasConcept C142462285 @default.
• W2806564260 hasConcept C159047783 @default.
• W2806564260 hasConcept C197934379 @default.
• W2806564260 hasConcept C203092338 @default.
• W2806564260 hasConcept C2777351918 @default.
• W2806564260 hasConcept C2780272996 @default.
• W2806564260 hasConcept C2781432083 @default.
• W2806564260 hasConcept C2908647359 @default.
• W2806564260 hasConcept C2993143319 @default.
• W2806564260 hasConcept C3013748606 @default.
• W2806564260 hasConcept C535046627 @default.
• W2806564260 hasConcept C71924100 @default.
• W2806564260 hasConcept C90924648 @default.
• W2806564260 hasConcept C98274493 @default.
• W2806564260 hasConcept C99454951 @default.
• W2806564260 hasConceptScore W2806564260C112705442 @default.
• W2806564260 hasConceptScore W2806564260C119060515 @default.
• W2806564260 hasConceptScore W2806564260C126322002 @default.
• W2806564260 hasConceptScore W2806564260C142462285 @default.
• W2806564260 hasConceptScore W2806564260C159047783 @default.
• W2806564260 hasConceptScore W2806564260C197934379 @default.
• W2806564260 hasConceptScore W2806564260C203092338 @default.
• W2806564260 hasConceptScore W2806564260C2777351918 @default.
• W2806564260 hasConceptScore W2806564260C2780272996 @default.
• W2806564260 hasConceptScore W2806564260C2781432083 @default.
• W2806564260 hasConceptScore W2806564260C2908647359 @default.
• W2806564260 hasConceptScore W2806564260C2993143319 @default.
• W2806564260 hasConceptScore W2806564260C3013748606 @default.
• W2806564260 hasConceptScore W2806564260C535046627 @default.
• W2806564260 hasConceptScore W2806564260C71924100 @default.
• W2806564260 hasConceptScore W2806564260C90924648 @default.
• W2806564260 hasConceptScore W2806564260C98274493 @default.
• W2806564260 hasConceptScore W2806564260C99454951 @default.

• next